Can EyePoint (EYPT) Turn DURAVYU’s Six‑Month Dosing Goal Into Lasting Competitive Advantage?

• EyePoint Pharmaceuticals recently presented at the Stifel 2026 Virtual Ophthalmology Forum and reiterated that top-line Phase 3 data for its wet age-related macular degeneration (AMD) therapy DURAVYU are expected to begin reading out in August, with a second pivotal trial to follow about two months later.
• Management highlighted 2026 as potentially transformative, emphasizing ambitions for DURAVYU to match a leading therapy on vision outcomes while maintaining safety and reducing treatment burden through every-six-month dosing.
• We’ll now examine how the upcoming DURAVYU Phase 3 readouts, and the push for six‑month dosing, could influence EyePoint’s investment narrative.

Outshine the giants: these 13 early-stage AI stocks could fund your retirement.

EyePoint Investment Narrative Recap

To own EyePoint today, you need to believe DURAVYU’s six month dosing can become a meaningful wet AMD option and eventually anchor the whole business. The Stifel update largely confirms timelines already on investors’ radars, so it reinforces, rather than changes, the key near term catalyst: August Phase 3 top line data. The biggest current risk remains clear: a single pivotal readout window that matters a lot for a company with minimal revenue and ongoing heavy losses.

The most relevant recent update is the May DSMC review, which recommended that the pivotal LUGANO and LUCIA trials continue as planned with no protocol changes and a favorable masked safety profile. That independent sign off, alongside confirmation that many patients have already received a third DURAVYU dose, supports confidence that the August and subsequent Phase 3 readouts are on track and will likely remain the central focus for EyePoint’s near term story.

Yet against that potentially transformative upside, investors should also be aware that EyePoint’s sharply lower revenue base and deepening net losses leave little room for error if DURAVYU were to...

Read the full narrative on EyePoint (it's free!)

EyePoint's narrative projects $334.0 million revenue and $60.6 million earnings by 2029.

Uncover how EyePoint's forecasts yield a $37.00 fair value, a 174% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts see this same August readout very differently, assuming revenue could reach about US$250.8 million and earnings around US$58.2 million by 2028, so if you are weighing this DSMC green light and upcoming data, it is worth remembering how widely expectations can vary and considering which version of EyePoint’s future you find most realistic.

Explore 3 other fair value estimates on EyePoint - why the stock might be worth over 6x more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your EyePoint research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free EyePoint research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate EyePoint's overall financial health at a glance.

Want Some Alternatives?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Find 46 companies with promising cash flow potential yet trading below their fair value.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.
• AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com